Table of contents
- Overview of Simvastatin research
- Conditions being studied
- Trial designs and comparison groups
- Who the studies are for
- Phases and main endpoints
- Key trial highlights
- What the results can mean for patients
Overview of Simvastatin research
These trials study Simvastatin in many different diseases, including pancreatitis, liver disease, stroke, eye disease, and cancer.[1][2][3] The studies are mostly interventional, which means researchers assign a treatment and then measure what happens.[1]
The trial phases range from Phase 2 to Phase 4, so the research includes both earlier testing and later studies in larger patient groups.[1][2]
Conditions being studied
One Phase 3 study tested whether Simvastatin could help prevent recurrent pancreatitis, which means repeated attacks of inflammation of the pancreas.[1]
Another study looked at people with severe hypertriglyceridemia, a condition with very high blood fat levels, and measured changes in fasting triglycerides after treatment.[2]
Several trials focus on liver and bile duct disease, including primary sclerosing cholangitis and liver fibrosis linked to alcohol-related liver disease.[6][5]
Other studies include people with Graves’ ophthalmopathy, spontaneous lobar intracerebral hemorrhage, ischemic stroke or transient ischemic attack, and selected advanced cancers.[4][3][7][8]
Trial designs and comparison groups
Some studies compare Simvastatin with placebo, which is an inactive treatment used for fair comparison.[1][5][6]
Some studies compare Simvastatin with no extra treatment or with another medicine, such as diclofenac in Graves’ ophthalmopathy.[4]
In the intracerebral hemorrhage study, the research compares continuing versus discontinuing statins, and Simvastatin is one of the statins included in the treatment options.[3]
In the cancer studies, Simvastatin is tested as part of a broader treatment plan, alongside other anti-cancer medicines.[7][8]
Who the studies are for
Each trial has a specific target group, so not every study is open to every patient.[1][3]
The pancreatitis trial enrolled people with recurrent pancreatitis and included 144 participants.[1]
The Graves’ ophthalmopathy trial enrolled people with mild to moderate disease and included 102 participants.[4]
The liver fibrosis trial studied adults with advanced fibrosis due to alcohol-related liver disease and planned 90 participants.[5]
The stroke-related trial focused on frail adults aged 70 and older with a recent ischemic stroke or transient ischemic attack, and it planned 600 participants.[8]
The intracerebral hemorrhage trial studied people with spontaneous lobar intracerebral hemorrhage who were already taking a statin, and it planned 1456 participants.[3]
The cancer trials focused on patients with advanced or metastatic gastrooesophageal carcinoma or metastatic pancreatic ductal adenocarcinoma.[7][8]
Phases and main endpoints
The studies include Phase 2, Phase 3, and Phase 4 trials, showing that Simvastatin is being tested in different stages of research.[1][2][3][4][5][6][7][8]
The main outcomes are different in each trial, but they all try to measure whether the treatment changes an important clinical result.[1]
In recurrent pancreatitis, the main outcome was recurrence of pancreatitis, meaning whether new attacks happened again.[1]
In severe hypertriglyceridemia, the main outcome was the percent change in fasting triglycerides at 26 weeks.[2]
In intracerebral hemorrhage, the main efficacy outcome was the risk of recurrent symptomatic bleeding over 24 months, and the safety outcome was major adverse cardiac and cerebrovascular events, often shortened to MACCE.[3]
In Graves’ ophthalmopathy, the study measured the clinical activity score and progression to severe disease after 6 months.[4]
In liver fibrosis, the key outcome was the change in fibrosis score on the Ishak scale after 24 months.[5]
In primary sclerosing cholangitis, the study tracked time to death, liver transplant listing, variceal bleeding, and certain cancers.[6]
In the cancer trials, the main outcomes were progression-free survival at 1 year and PFS between two treatment arms.[7][8]
In the frail stroke and TIA trial, the outcomes were MACE-free survival and health-related quality of life measured over 2 years.[8]
Key trial highlights
The recurrent pancreatitis study was a triple-blind, randomized controlled trial, which means the patient, the care team, and the assessors did not know who received which treatment.[1]
The PSC study was a randomized, double-blind, placebo-controlled multicenter study, which means it used several centers and compared Simvastatin with placebo in a blinded way.[6]
The liver fibrosis study also used a randomized, double-blind, placebo-controlled design, which is a strong way to compare treatment effects fairly.[5]
The stroke and TIA study looked at frail older adults, a group that may have different treatment needs and risks than younger people.[8]
The cancer trials tested Simvastatin together with other medicines, so they are studying it as part of combination treatment rather than alone.[7][8]
What the results can mean for patients
These trials are trying to answer practical questions about whether Simvastatin can help prevent disease return, slow disease worsening, improve survival, or reduce complications.[1][3][5][6]
The studies also show that the same medicine can be tested in very different illnesses, so the meaning of the results depends on the exact condition being studied.[4][7][8]
For patients, the most important point is that each trial has its own rules, its own target group, and its own main outcome, so the results cannot be mixed across all diseases.[1][2][3][4][5][6][7][8]
